Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27028359 | 0.86 | ALDH1A1 (0.53) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL15993406 | 0.85 | PKM (0.44) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4311423 | 0.82 | MAPT (0.47) | MAPTALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL27028348 | 0.82 | NOS1 (0.45) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL743661 | 0.81 | L3MBTL1 (0.58) | MAPTALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL3403936 | 0.81 | KDM4E (0.47) | MAPTALDH1A1MEN1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL4217802 | 0.80 | L3MBTL1 (0.56) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL2537598 | 0.79 | L3MBTL1 (0.54) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL27911792 | 0.79 | ALDH1A1 (0.63) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL19782877 | 0.79 | L3MBTL1 (0.56) | MAPTALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3291817-B1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3291817-B1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3291817-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
| CN-1711347-B | Use of metal complex compounds as oxidation catalysts | CIBA SC HOLDING AG | 2010-05-26 | — | — | CN | disclosed |
| US-7612010-B2 | Use of metal complex compounds as oxidation catalysts | CIBA SPECIALTY CHEMICALS CORP. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1703976-A2 | USE OF METAL COMPLEX COMPOUNDS COMPRISING PYRIDINE, PYRIMIDINE OR S-TRIAZINE DERIVED LIGANDS AS CATALYSTS FOR OXIDATIONS WITH ORGANIC PEROXY ACIDS AND/OR PRECURSORS OF ORGANIC PEROXY ACIDS AND H2O2 | Ciba Specialty Chemicals Holding Inc. (CH) | 2006-09-27 | — | — | EP | disclosed |
| EP-1703977-A1 | USE OF A COMPOSITION COMPRISING METAL COMPLEX COMPOUNDS AND POLYPHOSPHONATES AS CATALYSTS FOR OXIDATIONS | Ciba SC Holding AG (CH) | 2006-09-27 | — | — | EP | disclosed |
| EP-1556467-B1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA SC HOLDING AG (CH) | 2006-07-05 | — | — | EP | disclosed |
| US-20060052265-A1 | Use of metal complex compounds as oxidation catalysts | CIBA SPECIALTY CHEMICALS CORP. | 2006-03-09 | — | — | US | disclosed |
| CN-1711347-A | Use of metal complex compounds as oxidation catalysts | CIBA SC HOLDING AG (CH) | 2005-12-21 | — | — | CN | disclosed |
| WO-2005105303-A1 | USE OF METAL COMPLEXES HAVING BISPYRIDYLPYRIMIDINE OR BISPYRIDYLTRIAZINE LIGANDS AS CATALYSTS FOR REACTIONS WITH PEROXY COMPOUNDS FOR BLEACHING COLOURED STAINS ON HARD SURFACES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005068075-A1 | USE OF A COMPOSITION COMPRISING METAL COMPLEX COMPOUNDS AND POLYPHOSPHONATES AS CATALYSTS FOR OXIDATIONS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005068074-A2 | USE OF METAL COMPLEX COMPOUNDS COMPRISING PYRIDINE PRYIMIDINE OR S-TRIAZNE DERIVED LIGANDS AS CATALYSTS FOR OXIDATIONS WITH ORGANIC PEROXY ACIDS AND/OR PRECURSORS OF ORGANIC PEROXY ACID AND H2O2 | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-07-28 | — | — | WO | disclosed |
| EP-1556467-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | Ciba SC Holding AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039934-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | PDE2A, PDE12, PDE7B | MAPT 1106/4885ALDH1A1 718/4885L3MBTL1 4540/4885 |
| US-20060052265-A1 | Use of metal complex compounds as oxidation catalysts | AP1M1, MLX, SOD1 | MAPT 3288/4885ALDH1A1 2149/4885L3MBTL1 630/4885 |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE7B | MAPT 1106/4885ALDH1A1 718/4885L3MBTL1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.